Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.
Himisha Beltran, MD, associate professor of medicine and physician in the Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology at Dana-Farber Cancer Institute and Harvard Medical School, discusses the significance of genomic sequencing in prostate cancer.
Not all men with prostate cancer will respond to PARP inhibitors; thus, the role of genomic sequencing has become increasingly important, says Beltran.
As such, the field of prostate cancer continues to enhance its knowledge of genomic sequencing in metastatic disease, Beltran says.
Further refining genomic sequencing may provide insight into the role of DNA repair aberrations, the natural history of rare variants, the impact of co-occurring alterations, and the development of resistance, Beltran adds.
Ultimately, harnessing genomic and non-genomic information will continue to play a critical role in treatment selectionfor men with prostate cancer, Beltran concludes.